Latest News

The venture aims to deliver comprehensive active pharmaceutical ingredient (API) services, covering everything from initial development stages through full-scale commercial production.

The company showcased three new angiography platforms—Artis genio, Artis icono.explore, and Artis icono.vision—which harness artificial intelligence to enhance the precision of liver cancer embolization treatments.

The company formalized its commitment with South Korea’s Ministry of Health and Welfare to enhance the bio-healthcare industry by supporting international clinical trials and advancing research for innovative medicines.

Abbott engineered the HERO reader to be 60% lighter than its predecessor, making it practical for daily use and convenient enough for patients to carry during travel.

The agreement includes a USD135 million upfront payment to Sino Biopharmaceutical for worldwide rights, with up to USD1.39 billion in potential milestone payments based on development, regulatory approvals, and sales.

The proprietary CXLens system delivers patterned ultraviolet light to reshape the cornea while keeping the epithelium—the eye’s protective outer layer—completely intact.

This strategic approach aligns with President Bola Tinubu’s broader vision to unlock the healthcare value chain by empowering local pharmaceutical industries.

The Israeli pharmaceutical company will receive the funding over four years to support ongoing trials of the anti-TL1A antibody, which Teva is co-developing with Sanofi.

The newly cleared system allows clinicians to mechanically loosen and remove debris and microorganisms from wounds during powered irrigation procedures.

ATG-201 is designed as a bispecific molecule that binds to both CD3 on T cells and CD19 on B cells, effectively recruiting the body’s own immune system to destroy disease-causing B cells.